Public Health

Upcoming Events


Subscribe to Newsletter(s)

Asia-Europe Foundation will use the information you provide on this form to send you updates about our activities. Please confirm that you would like to hear from us through the following means:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at We will treat your information with respect. For more information about our privacy practices please visit our website. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

High-level Meeting on Universal Health Coverage in an era of Antimicrobial Resistance

Project Period: Contact: Department: Programme: Theme:
2020 Riko KIMOTO Sustainable Development & Public Health Department ASEF Public Health Network Public Health



The emergence and spread of antimicrobial resistance (AMR) are some of the biggest issues in modern medicine and will have significant negative influence beyond the health sector as threats to global health, food security, and development. This will negatively affect the gains of the Sustainable Development Goals (SDGs). The gravity of AMR is often equated to that of climate change. Global Leaders pledged to fight against AMR at the 71st session of United Nations General Assembly (UNGA) in 2016. This commitment at the highest level moved many countries to develop National Action Plans (NAPs) to combat AMR. However, implementing NAPs is proven to be a challenge for many countries – the beliefs and practices of both practitioners and the public on the use of antibiotics have become entrenched over several decades, and this has in effect exacerbated the spread of AMR.

Most of the current health systems in many countries were developed under the assumption of the availability of effective and affordable antimicrobials. Nonetheless, the effectiveness of antimicrobials is no longer guaranteed due to AMR. Further, AMR places the sustainability of health systems in danger. It is estimated that AMR amounts to Euro 1.5 billion per year in health care costs and productivity losses in the European Union alone[1]. At the same time, increased access to antimicrobials by universal health coverage (UHC) could increase the risk of AMR without appropriate regulation or surveillance in place. Therefore, existing health systems should be updated to mitigate AMR, and achieving UHC requires to take AMR into account especially in an era with the growing problems of resistance to antimicrobials.

In 2020, ASEF PHN is hosting a multi-country, high-level Meeting focusing on UHC in an era of AMR, and how the governments can integrate a concern for AMR in UHC strategies.


The overall aim of this High-level Meeting is to facilitate an agreement between governments and other stakeholders on practical ways to integrate a concern for AMR into UHC strategies.This includes drawing a linkage between NAPs and strategies for UHC. The specific objectives are:

  • To bring together officials with responsibilities for AMR and UHC and other stakeholders to identify parts of health systems that require modification in order to address the risk of AMR within the scope of UHC
  • To identify practical actions for the points identified above, and connect them to the role of the leadership within health systems and governance structure in addressing AMR
  • To agree on priorities for international cooperation between Asia and Europe to support progress towards sustainable UHC while containing risks of emerging infectious diseases as well as AMR

Target Audience

The High-level Meeting will address three target audiences: 1) senior-level health officials who are working in the area of UHC; 2) senior-level health officials who are working in the area of AMR; and 3) private company representatives with an involvement in the production, supply and use of antibiotics. The target audience more specifically includes:

  • Senior-level officials, advisors, and/or other decision-makers from Ministries of Health of ASEM Partners or equivalent who work in the area of UHC and/or AMR
  • Chief/directors from national health agencies of ASEM Partners or equivalent who work in the area of UHC or AMR
  • Senior-level officials from Ministries of Finance and Foreign Affairs of ASEM Partners
  • Representatives of international organisations and non-profit organisations (NGOs)
  • Representatives of private sectors whose work is closely related to AMR, such as pharmaceutical industries, private hospitals, and insurance companies




This project is sponsored by the Government of Japan.
We use cookies to optimise the use of our website. Read our cookie policy and privacy policy. Yes, I'm ok with that.